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Purpose: Genetic testing in hypertrophic cardiomyopathy (HCM)
has long relied on Sanger sequencing of sarcomeric genes. The
advent of next-generation sequencing (NGS) has catalyzed routine
testing of additional genes of dubious HCM-causing potential. We
used 19 years of genetic testing results to define a reliable set of
genes implicated in Mendelian HCM and assess the value of
expanded NGS panels.
Methods: We dissected genetic testing results from 1,198 single-
center HCM probands and devised a widely applicable score
to~identify which genes yield effective results in the diagnostic
setting.
Results: Compared with early panels targeting only fully
validated sarcomeric HCM genes, expanded NGS panels allow
the prompt recognition of probands with HCM-mimicking
diseases. Scoring by “diagnostic effectiveness” highlighted that
PLN should also be routinely screened besides historically
validated genes for HCM and its mimics.
Conclusion: The additive value of expanded panels in HCM
genetic testing lies in the systematic screening of genes associated
with HCM mimics, requiring different patient management. Only
variants in a limited set of genes are highly actionable and
interpretable in the clinic, suggesting that larger panels offer limited
additional sensitivity. A score estimating the relative effectiveness of
a given gene’s inclusion in diagnostic panels is proposed.
Genetics in Medicine (2019) 21:284–292; https://doi.org/10.1038/s41436-
018-0046-0
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM, OMIM 192600) is an
inherited heart disease affecting approximately 1 in 500
individuals,1 defined by the presence of increased left
ventricular wall thickness (≥15 mm in adults) that is not
explained by abnormal loading conditions.2 Despite ever-
increasing knowledge in understanding its genetic architec-
ture, several issues remain unresolved. Reduced penetrance,
allelic heterogeneity, and variable expressivity are long-known
complicating factors in identifying causative variants.3,4
Furthermore, the existence of physiologically diverse HCM-
mimicking diseases often renders differential diagnosis
difficult for the cardiologist, despite a well-defined diagnostic
framework for cardiomyopathies.5,6 Genetic testing has
progressively led to identification of the pathogenic variant
in up to 60% of patients, classically relying on Sanger
sequencing of sarcomere genes robustly associated with HCM
through family studies in large pedigrees (MYH7, MYBPC3,
TNNT2, TPM1, MYL2, MYL3, TNNI3, and ACTC1).7–9 The
advent of increasingly cost-effective next-generation sequen-
cing (NGS) solutions has triggered a large number of
candidate gene studies, often leading to gene–HCM associa-
tions based only on the identification of rare variants in
patients, without controlling for the background population
variation. Such genes have been subsequently included in
expanded diagnostic panels, carrying the hope of reducing the
proportion of affected individuals in whom the causing defect
remains elusive. Following the release of the Exome
Aggregation Consortium (ExAC) population database,10
many of the associations with HCM proposed in the absence
of solid segregation studies have been critically revised and
judged to be based on insufficiently stringent criteria.11 To
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contribute to the definition of a reliable core set of genes
implicated in Mendelian HCM, we developed and applied a
widely applicable gene- and disease-specific score (“diagnostic
effectiveness” (DEff)) to estimate the relative effectiveness of a
given gene in a diagnostic panel.
MATERIALS AND METHODS
HCM cohort
Careggi University Hospital is a large National Health Service
facility integrated with the University of Florence. Over the
past four decades, a dedicated cardiomyopathy unit has
routinely evaluated and followed >1,600 patients with forms
of HCM. Since 1998, all were offered genetic testing and 1,198
probands were sequenced until November 2016: 585 using
Sanger sequencing of 3 or 8 sarcomeric genes and 613 using
NGS of 12 or 48 genes associated with HCM (Fig. 1a). The
majority of probands were originally evaluated at our center
(78.5%), with the rest referred for specialist evaluation from
18 other Italian hospitals (Fig. 1b). All participants gave
written informed consent and the study was approved by the
relevant regional research ethics committee.
Genetic testing
Routine genetic testing for HCM patients was introduced at
our center in 1998 using Sanger sequencing and targeting the
first three genes associated with HCM: MYH7, MYBPC3, and
TNNT2.12–14 The set of targeted genes was expanded in 2005
to include the other five sarcomeric genes irrefutably
associated with HCM (TPM1, MYL2, MYL3, TNNI3, and
ACTC1). Following the expansion of NGS and its widespread
adoption in clinical practice (fueled by its decreasing prices
and escalating throughput), genetic screening by Sanger
sequencing was replaced with NGS at our center in early





















































































(111 genes; 48 associated with HCM)
8 validated sarcomeric genes
GLA, LAMP2, PRKAG2 and, TTR
Fig. 1 Hypertrophic cardiomyopathy cohort and gene panels. a Adoption of Sanger sequencing and next-generation sequencing (NGS) assays from
1998–2016, alongside the number of probands tested on each panel included in the study. The total number of genetic tests performed each year on
hypertrophic cardiomyopathy (HCM) probands and their family members is also displayed (red line). The “8 validated sarcomeric genes” were MYH7,
MYBPC3, TNNT2, TPM1,MYL2,MYL3, TNNI3, and ACTC1. Details of the 48 genes associated with HCM and targeted by the Pan Cardiomyopathy Panel are
available in Supplementary Table S1 online. b Referring centers of origin for the HCM probands sequenced with NGS panels (n= 613) from 2013 onwards.
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on a 111-genes Pan Cardiomyopathy Panel, also targeting 48
genes with at least one published association with primary
HCM in the literature (Supplementary Table S1 online). This
gene selection rationale led to the inclusion of some genes
primarily associated with RASopathies but also implicated in
HCM, such as RAF1, and the exclusion of others not
implicated in primary HCM before 2013, such as BRAF. In
addition, as infant-onset phenotypes such as Pompe disease
are assessed at the nearby Meyer University Hospital (one of
the largest Italian pediatric hospitals) rather than at Careggi
University Hospital, genes associated with such conditions
were not included in the analysis of this cohort. From 2014, a
smaller panel including only the eight validated sarcomere
genes (“group α genes”) and four genes associated with HCM
mimics (GLA, LAMP2, PRKAG2, and TTR—“group β genes”)
was routinely adopted. Since then, the Pan Cardiomyopathy
Panel (targeting group α, group β, and 36 additional genes
associated with HCM defined as “group γ”) was used only on
a subset of HCM patients with atypical disease features
(Fig. 1a). This two-panel strategy was adopted following a
diagnostic resource optimization rationale, as patients with a
classic HCM phenotype were most often either genotype
negative, or positive for a sarcomeric variant. Details on
sequencing and bioinformatics data processing are available
in Supplementary Note 1. All variants reported in this work
were validated by Sanger sequencing and classified as
pathogenic (P), likely pathogenic (LP), or of uncertain
significance (VUS) following guidelines and standard criteria
available at the time of testing. For validation purposes, all
variants were also reclassified within this work according to
the latest variant interpretation guidelines15 using Cardio-
Classifier16 or InterVar17 (for variants in genes that
CardioClassifier does not analyze). Of note, this automatic
reclassification effort could not account for some guideline
criteria requiring manual curation by the geneticist (details in
Supplementary Note 2), as a full reanalysis of the results from
19 years of genetic testing was beyond the scope of our study.
Derivation of DEff
The main objective of this work is to contribute to the
definition of a core set of genes reliably implicated in
Mendelian HCM and its mimics. To do so, we computed
gene-specific parameters derived from the frequency of rare
(minor allele frequency (MAF) < 0.01%) and potentially
clinically significant variants (classified as P, LP, or VUS)
identified in patients, and the background population
variation of rare coding variants derived from the ExAC.
The MAF cutoff of 0.01% to define rarity was selected in the
light of recent literature on the genetic architecture of
HCM,11,18 considering any variant observed at higher
frequencies too common to plausibly cause HCM under
Mendelian dominant inheritance.
The frequency of rare and potentially clinically significant
variant carriers in patients, defined for any gene as:
Frare P;LP;VUS ¼ Number of HCMpatients with1 rare P;LP; orVUSNumber of HCMpatients
is suggestive of the contribution of the gene to the overall
disease burden. The proportion of Frare P,LP,VUS constituted by
P/LP variant carriers (calculated without including VUS-only
carriers in the numerator) reflects the actionability for cascade
screening (ACS) of the variation in the gene, as VUS are not
screened in family members, with the test result remaining
inconclusive and not actionable. We therefore defined:
ACS ¼ Frare P;LP
Frare P;LP;VUS
Many variants are scarcely characterized and often the only
feature suggesting potential pathogenicity is their rarity in
population databases, which in absence of additional evidence
leads to classification as VUS.15 On this basis, we can assume
the overall frequency of rare P/LP/VUS variants in a gene to
be approximately equal to the overall frequency of rare
variants:
Frare P;LP;VUS ffi Frare
Each gene’s Frare is also computable on population datasets
such as ExAC, assuming rare variants to occur in distinct
individuals and thus enabling estimation of the gene’s
background population variation. Here, we compare the
frequency of rare P/LP/VUS variants in HCM patients with
that of rare variants in ExAC over each gene. Patients are not
expected to be enriched for benign variants; therefore, a high
FrareHCM:FrareExAC ratio means that those affected carry
rare variants several times more often than controls, and
reflects a high likelihood for any variant in the gene in
question identified in a patient to be pathogenic. This case-to-
control burden ratio de facto represents the diagnostic
interpretability (DI) of variation in the gene, defined in this
work as:
DI ¼ Frare P;LP;VUSHCM
Frare ExAC
DI is influenced by both the number of rare benign variants
and the penetrance of pathogenic variants in the gene in
question, as genes with higher-penetrance variants and/or
particularly intolerant to genetic variation will be character-
ized by low FrareExAC and therefore higher DI scores.
High ACS and DI do not necessarily co-occur, as variation
in a gene may be highly actionable and poorly interpretable
(e.g., pathogenic variants occurring in a specific hotspot, with
a high background variation rate in the rest of the gene), or
vice versa (e.g., novel gene with rare and poorly characterized
variants, but significantly more common in patients than
controls).
Since the effectiveness of a gene when included in
diagnostic panels depends on both actionability and inter-
pretability, we define:
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We used DEff to measure the effectiveness of each gene
when screened in HCM, and replicated DEff scores following
automated variant reclassification per the latest ACMG
guidelines,15 and on a larger published HCM cohort totaling
up to 6,179 patients.18
Statistical methods
All statistical analyses were performed using R. Comparisons
of proportions were done by means of two-tailed Fisher's
exact test, while a Mann-Whitney U-test was adopted to
compare score distributions. A nested binomial regression
model comparison by means of a likelihood ratio test was
used to assess the predictivity of the genetic test date on test
results.
RESULTS
Variation in sarcomeric genes and comparison of NGS and
Sanger
In total, 1,198 probands with a diagnosis of HCM underwent
genetic testing. The majority were males (63.3%) and white
(98.1%), with 27.2% reporting a positive family history of
HCM. Age at diagnosis (mean ± SD) was 46.3 ± 19.3 years,
and patients presented with a cardiac phenotype typical of
HCM, with a maximal left ventricular wall thickness of 20.5 ±
5.4 mm and left ventricular ejection fraction of 62.7 ± 10.9%
(Supplementary Table S2 online). All probands were screened
for variants in MYBPC3, MYH7, and TNNT2, and 1,052
(87.7%) were also evaluated on the other five validated HCM
sarcomeric genes (TNNI3, MYL2, MYL3, TPM1, and ACTC1)
(Fig. 1a). Of these 1,052 probands screened on all 8 group α
genes, 491 (46.7%) harbored ≥1 variant classified P, LP, or
VUS at the time of testing. The yield was comparable between
Sanger and NGS, both in total (211 (48.1%) vs. 280 (45.7%),
respectively; P= 0.45) and with regard to individual genes
(Table 1).
Conversely, a significant difference was observed between
the early 146 probands, tested between 1998 and 2005 only on
MYBPC3, MYH7, and TNNT2, and the other 1,052 probands
tested on all group α genes. Comparing the yield of P/LP/VUS
variants in these three sarcomeric genes, the subset of
probands tested early on the 3 gene panel was significantly
enriched for variants (78 (53.4%) vs. 447 (42.5%); P= 0.02).
This difference is partly explained by two distinct founder
effects, causing an enrichment in Tuscan patients of otherwise
rare HCM-associated variants NM_000256.3 (MYBPC3):
c.772 G > A and NM_000257.3 (MYH7):c.2606 G > A. These
regional founder effects were already well known to the
clinical community when genetic testing started in 1998;
hence, the vast majority of carriers were tested early, when the
Sanger panels were in use (69/585 (11.8%) Sanger-evaluated
founder variant carrier probands versus 29/613 (4.7%) NGS-
evaluated probands; P= 7.7 × 10−6).
Expanded gene set and scoring by DEff
As the adoption of NGS from 2013 allowed the systematic
screening of a higher number of genes, the results obtained on
the 613 NGS-screened probands were analyzed in detail and
used to compute all gene-specific scores proposed in this
work. In doing so, we dissected variation by gene, diagnostic
classification, and rarity, and compared cumulative rare
variant frequencies observed in HCM patients with those in
ExAC (Fig. 2). The full set of analyzed variants, alongside
their frequency and diagnostic interpretation details, is
available in Supplementary Table S3 online.
Variants originally classified P/LP/VUS were detected in 31
of 48 HCM-associated genes targeted by NGS panels.
Nineteen probands (3.1%) were diagnosed with metabolic
or infiltrative forms closely mimicking sarcomeric HCM
(Fig. 3), including transthyretin-related amyloidosis (n= 6,
1%), Fabry disease (n= 5, 0.8%), Danon disease (n= 4, 0.7%)
and PRKAG2-related HCM (n= 4, 0.7%), following the
identification of variants in group β genes.
Of note, only rare variants (MAF < 0.01% in ExAC) were
considered in the derivation of the gene-specific scores
proposed. This was to minimize the effect of false positive
P/LP variant classifications and enhance replication on
published cohorts where variants with this MAF were
reported.
Group α, β, and γ genes were characterized by overall ACS
(i.e., the proportion of rare P/LP variants of the total rare P/
LP/VUS variation in the gene in patients; median (inter-
quartile range): 0.74 (0.5–0.83), 0.55 (0.44–0.65), and 0
(0–0.75), respectively) and DI ratios (i.e., the ratio of rare,
potentially pathogenic variants observed in patients versus
ExAC controls; 7.2 (5.0–9.8), 4.6 (3.1–6.4), and 1.5 (1.1–2.5),
respectively) (Fig. 4).
The DEff (i.e., the gene’s ACS multiplied by its DI) of group
α genes was comparable to that of group β (P= 0.37), but
Table 1 Proportion of P/LP/VUS variant carriers for the
patient subsets screened with Sanger versus NGS, over the

























MYH7 71 (16.2%) 78
(12.7%)
149 (14.2%) 0.34
TNNT2 12 (2.7%) 18 (2.9%) 30 (2.9%) 1
TNNI3 6 (1.4%) 23 (3.8%) 29 (2.8%) 0.17
MYL2 7 (1.6%) 5 (0.8%) 12 (1.1%) 0.51
MYL3 0 (0.0%) 7 (1.1%) 7 (0.7%) 0.18
TPM1 2 (0.5%) 4 (0.7%) 6 (0.6%) 1
ACTC1 1 (0.2%) 2 (0.3%) 3 (0.3%) 1
HCM, hypertrophic cardiomyopathy; LP likely pathogenic; NGS next-generation
sequencing; P pathogenic; VUS variant of uncertain significance.
Data refer to the 1,052 probands tested on all 8 genes. Reported P values are
adjusted for testing eight genes with the false discovery rate method.
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both these gene sets had values significantly higher than
group γ (P= 0.006 and P= 0.025, respectively; α: 4.9
(2.4–8.3), β: 2.6 (1.4–4.3), γ: 0 (0–0.7); Fig. 4). These results
were replicated when all variants were classified according to
the most recent interpretation guidelines15—although some
criteria requiring manual curation were excluded (see
Materials and Methods and Supplementary Note 2)—with
groups α and β characterized by comparable DEff values (P=
1), which were higher than those of group γ genes (P= 0.006
and P= 0.02, respectively).
An exception in group γ is PLN (DEff= 12.2, independent
of adopted guidelines), which is rarely mutated but char-
acterized by high actionability and interpretability. Replicated
DEff, computed for a published cohort of 6,179 patients,18
showed group α and β values to be comparable to those
obtained in our data (P= 0.96 and P= 0.56, respectively). A
formal comparison of group γ DEff value distribution was not
performed as only four variant-positive group γ genes were
sequenced in the replication cohort (ACTN2, MYOZ2, NEXN,
and PLN). While the replication DEff of ACTN2, MYOZ2,
and NEXN was 0, PLN’s replication DEff score was 1.9, which
is lower than its discovery value but in line with that of fully
validated group α and β genes in our data. This makes it an
outlier, being over 1.5 interquartile range points above the
third quartile with respect to group γ (Fig. 4). All discovery
and replication DEff values are provided in Supplementary
Table S4 online.
Of the eight variants in group γ genes originally classified
P/LP (following variant interpretation guidelines available at
the time;11 Supplementary Table S5 online), only three (in
PLN, ACTN2, and MYOZ2) are considered LP by the most
recent guidelines.15 As far as variants’ population frequency is
concerned, we observed a significant enrichment in common
variants (MAF > 0.01%) in group γ genes compared with
group α and β genes (24/41 (58.5%) vs. 38/342 (11.1%)
variants, respectively; P= 3.0 × 10−11).
Finally, the genetic test date was predictive of the test result,
independent of the referring hospital, gene panel, presence of
founder effect variants, and variant interpretation guidelines
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Fig. 2 Cumulative variant frequencies observed in hypertrophic cardiomyopathy patients compared with those in the Exome Aggregation
Consortium. Proportion of hypertrophic cardiomyopathy (HCM) probands evaluated by next-generation sequencing (n= 613) carrying clinically reportable
variants (left-hand side bar for each gene). Proportions are divided into “rare” (minor allele frequency (MAF) < 0.01% in the Exome Aggregation Consortium
(ExAC); above 0 on the y axis) and “common” (MAF > 0.01% in ExAC; below 0 on the y axis). Variants with MAF > 0.01% are unlikely to be truly disease
causing, as recently demonstrated.26 Variation in HCM is also divided into pathogenic (P: red, rare; pale red, common), likely pathogenic (LP: orange, rare;
pale orange, common), and variants of uncertain significance (VUS: yellow, rare; pale yellow, common). Light blue bars (right-hand side for each gene)
represent the proportion of rare protein-altering variant carriers in ExAC. Robustly validated disease genes (turquoise background) were sequenced in all
probands screened using next-generation sequencing (n= 613), while other genes (purple background) were sequenced on a subset of 171 probands
(Fig. 1). Genes associated with syndromic forms of HCM are indicated in bold. For example, MYBPC3 is characterized by features typical of a major disease
gene: strong rare variation excess in patients (left-hand side bar) versus ExAC (right-hand side bar), reflective of high diagnostic interpretability, and a high
proportion of P/LP variants (red/orange), indicating high actionability for cascade screening (see Materials and Methods for derivation). Conversely, MYPN is
characterized by all variants originally classified as P/LP being too common in ExAC to be pathogenic, the frequency of rare variant carrier patients being
essentially equal to the background population level (low diagnostic interpretability), and all rare variants in patients being VUS (null actionability for cascade
screening)
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higher likelihood of yielding a positive result (P/LP/VUS
identified).
DISCUSSION
Since 1989, when HCM was first mapped to a locus on
chromosome 14 and MYH7 was robustly associated with
disease for the first time,12 variants in 7 other genes encoding
proteins of the cardiac sarcomere (MYBPC3, TNNT2, TPM1,
MYL2, MYL3, TNNI3, and ACTC1) have been indisputably
linked to HCM 7 by multiple linkage studies in large
pedigrees. Genetic testing is historically reported to identify
a disease-causing variant in 40–60% of patients fulfilling
HCM diagnostic criteria, with a large predominance of
pathogenic variants in these eight genes (group α).8,9
Consistently, we found ≥1 variant of clinical significance
(VUS, LP, or P) in group α genes in 491 (46.7%) probands
screened on all 8 genes. Phenotypic and demographic
characteristics of the analyzed HCM cohort resemble those
of the typical HCM patient group in an Italian hospital, with a
male-to-female ratio close to 3:2 and a predominance of
Caucasian individuals.
While Sanger sequencing and NGS pose radical differences
—with NGS characterized by a lower per-base cost and higher
sequencing throughput—it has been established that the two
techniques are characterized by comparable accuracy. In line
with previously published reports,19,20 we did not observe
significant yield discrepancies over the 8 group α genes
between Sanger sequencing (n= 585 patients) and NGS (n=
613 patients).
Given the many dubious associations of nonsarcomeric
genes with HCM that have been proposed since 1999,21 we
devised the novel gene- and disease-specific DEff to measure
the utility for inclusion of a given gene in a panel. DEff
summarizes information on a gene's potential for family
cascade screening and the effective likelihood of pathogenicity
of its variation when found in affected patients, with the
underlying assumption that the DEff scores observed for fully
validated disease genes represent the golden standard for
inclusion in diagnostic panels. Not surprisingly, DEff scores
were significantly higher overall for group α and β genes
associated with HCM or its mimics based on complete and
irrefutable evidence, compared with group γ genes. Approxi-
mately 71% of probands screened with NGS (n= 436)
underwent genetic testing before publication of the latest
variant interpretation guidelines;15 therefore, retaining the
original variant classification represents a limitation of this
work. To overcome this, we performed automated reclassifi-
cation of all variants using CardioClassifier16 and InterVar,17
but without the possibility of evaluating parameters requiring
manual curation by the geneticist (see Materials and Methods
and Supplementary Note 2). Nonetheless, this represents a
conservative evaluation of variants’ pathogenicity, under-
rating the disease-causing potential of group α and β genes
especially (for which there is more published segregation and
functional evidence). However, using these updated and
conservative classifications, the DEff scores of groups α and β
were again observed to be significantly higher than group γ,
underscoring the reliability of DEff.
Within group γ, PLN was an upper outlier in terms of its
DEff score (a result replicated for a larger HCM cohort of
2,167 patients). Thus, although the low frequency of PLN
variants has understandably hampered the availability of large
affected families with a clear HCM phenotype to prove co-
segregation, we suggest PLN for routine incorporation in
diagnostic gene panels for HCM. As DEff is intrinsically based
on observed variation, we did not calculate it for the variant-
negative genes (all in group γ). As such—and as the number
of patients sequenced on the Pan Cardiomyopathy Panel was
relatively low (n= 171)—we acknowledge that if any group γ
gene has a rare pathogenic role, it could have remained
undetected in this analysis (especially for genes that were not






















Fig. 3 Cardiac magnetic resonance images of example patients with sarcomeric hypertrophic cardiomyopathy and three of its mimics
identified in our cohort. Top: cine two-dimensional images in short-axis view using balanced turbo-field echo sequencing. Bottom: late gadolinium
enhancement patterns (circled in yellow) in four-chamber (first and last panel) and short-axis view, using spoiled inversion recuperation turbo-field echo
three-dimensional sequencing. LV left ventricle; RV right ventricle; VS ventricular septum
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gene-specific metrics for such genes in large cohorts is
warranted, although it has previously been observed that, for
most of these genes, there is little or no evidence for a
causative role in HCM.11,22 Despite the reduced size of the
subset with sequenced group γ genes, the remaining 18
variant-positive γ genes performed poorly in terms of
actionability and/or interpretability, underscoring the need
for sole inclusion in diagnostic panels of those genes
associated with disease with rigorous evidence. Particular
cases are ACTN2 andMYOZ2, which are not enriched for rare
variants in HCM either in our cohort (P= 0.12 and P= 0.36
versus ExAC, respectively) or larger published clinical case
series,18,21 but with the same variants detected in our patients
reported to co-segregate with HCM in large pedigrees.23,24 In
such cases, allele-specific genetic testing is informative, as
opposed to screening for variants over the complete coding
sequence, with the majority of variants in patients likely to
represent harmless background variation. The fact that the
original P/LP classification held with updated guidelines for
only three group γ variants suggests that the DEff of group γ
genes computed here represents a conservative overestimate,
and highlights the importance of a periodic revision of
identified variants’ pathogenicity classification in diagnostic
laboratories. These findings support the idea that inclusion of
most γ genes in HCM diagnostic panels lacks utility, yielding
uninterpretable and unactionable results. Per current variant
interpretation guidelines,15 most rare variants in such poorly
validated genes would be considered VUS, causing further
uncertainty for patients, with the risk of subjective and
incorrect interpretation of an inconclusive result.25
One of the features considered as strong evidence for a
variant being benign by current guidelines is the MAF being
too high for the disease in question.15 Data from projects such
as 1000 Genomes, the Exome Sequencing Project, and
especially ExAC10 have demonstrated how many variants
previously deemed to be pathogenic are present at population
frequencies incompatibly high with Mendelian dominant
disease causation. This also affects variation in validated
HCM genes in which we observed 38/342 (11.1%) variants
with a MAF > 0.01%, most likely representing benign
bystanders of other disease causes. However, compared with
the 12 validated group α and β genes, group γ genes are
strongly enriched in common variants (P= 3.0 × 10–11),
providing additional evidence against their HCM-causing
potential. After completion of this work, more stringent,
variant-specific allele frequency adjustment has been pro-
posed26—with 0.004% estimated as the maximum credible
allele frequency for any HCM-causing variant. Such a strategy
also controls for differences between ethnic groups, correcting
each variant’s MAF based on the highest observed in the
different ethnic subgroups. The application of such a valid
and innovative framework in our case affected only 7 variants
(in 5 different genes and all carried by a single patient) of the
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Fig. 4 Group α, β, and γ genes characterized by overall actionability for cascade screening and diagnostic interpretability ratios. Per-gene
diagnostic interpretability (DI) versus actionability for cascade screening (ACS). DI describes the relative frequency of potentially pathogenic variants in
patients compared with controls corresponding, in the diagnostic setting, to the odds of a variant detected in a patient to be causative (e.g., based on our
data, a potentially pathogenic variant detected in MYH7 in a patient is approximately nine times more likely to be causative than benign). ACS reflects the
proportion of potentially pathogenic variants detected in patients that are actionable for cascade screening family members (e.g., approximately 70% for
MYH7). The product of the two metrics yields the diagnostic effectiveness (DEff) of each gene (inset; see Materials and Methods), which summarizes the
relative utility for inclusion of a given gene in a diagnostic panel and is significantly different for groups α and β versus group γ genes. Notably, the only
group γ gene with a DEff comparable to scores of fully validated group α and β genes is PLN. Single DEff values of representative genes with high values of
ACS and DI are displayed to the right of the inset, where TPM1 (DEff= 1.9) was excluded for improved readability. NS, not significant
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HCM (Supplementary Table S6 online), thus not impacting
our results. Of note, all these variants are classified VUS by
current guidelines,15 and only 3 have a MAF > 0.01% in
specific ethnic groups, suggesting that the small proportion of
non-Caucasian cases included (<2%) and the usage of the
entire ExAC dataset did not affect our conclusions.
Finally, the observation of diagnostic yield dropping over
time independent of potential confounders, as highlighted by
multivariate regression modeling, is in line with previously
published reports in the context of cardiomyopathies and
arrhythmias.22,27
In conclusion, our data highlight that only genes
characterized by incontrovertible evidence of an association
with HCM or its metabolic mimics yield interpretable and
actionable results in the diagnostic setting, with equal results
obtained with Sanger sequencing and NGS. In our case, the
specific advantage of an expanded gene panel was the
possibility to promptly identify 19 patients (3.1%) affected
with HCM mimics through a “genotype-first” approach,
enabling early diagnosis of these conditions—sometimes
indistinguishable from classic HCM in the clinic—and
requiring radically different patient management. Such a
change in clinical management represents additional action-
ability—on top of that represented by cascade screening in
families—characterizing genes associated with metabolic or
infiltrative HCM-mimicking disease. The adoption of NGS
thus allowed a small set of additional important genes to be
routinely screened at little extra cost, with HCM mimics
previously diagnosed at our center through traditional
laboratory assays following specialist clinical assessment, in
which the presence of the HCM-mimicking disease was at
least suspected. Recognizing such conditions in the initial
stages is key, given the better response to treatment of Fabry
patients when enzyme replacement therapy is started
earlier,28 and given that sudden cardiac death is a frequent
cause of death in Danon disease.29 Through the newly
devised metric DEff, we suggest that PLN should be treated as
a “core”—although rare—HCM gene, whereas for ACTN2
and MYOZ2 only specific screens for plausibly pathogenic
variants would be effective.
DEff is widely applicable in the context of Mendelian
diseases, and we believe it will be particularly useful for
genetically heterogeneous conditions such as HCM for which
the number of genes irrefutably associated with disease
constitutes only a small proportion of all implicated genes.
Such diseases can be problematic in the diagnostic setting
when it comes to choosing which genes to include in panels.
On the one hand, screening for only fully validated genes may
cause the number of false negative tests to increase, while on
the other hand, being overly inclusive and screening all
implicated genes would cause an increase of inconclusive—
and even false positive—findings. Both scenarios represent
situations that are detrimental for patients and their family
members. In this respect, DEff is intended as a score that can
aid geneticists in performing a balanced selection of genes to
be included in diagnostic panels, and that can be considered
as additional evidence by gene curation efforts such as
ClinGen,30 created to overcome such ambiguities.
As a whole, these data support the concept that screening a
large number of genes offers limited additional sensitivity in
HCM, and that novel approaches to investigate its underlying
complex—and most likely not only familial31,32—etiological
background should be developed.
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